Aura Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AURA Nasdaq 2836 www.aurabiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aura Biosciences, Inc.

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference - Nov 24th, 2025 2:05 pm
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward - Nov 20th, 2025 6:00 pm
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 13th, 2025 5:00 am
Owning 43% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), - Sep 25th, 2025 4:25 am
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 5:00 am
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth - Aug 15th, 2025 4:08 am
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights - Aug 13th, 2025 5:00 am
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - May 15th, 2025 7:32 am
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants - May 15th, 2025 4:10 am
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights - May 15th, 2025 4:01 am
Aura Biosciences to Participate in Upcoming Investor Conferences - May 1st, 2025 2:01 pm
Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? - Apr 6th, 2025 2:35 pm
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - Apr 2nd, 2025 5:00 am
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Mar 24th, 2025 2:01 pm
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress - Mar 24th, 2025 5:00 am
With 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interest - Mar 24th, 2025 4:00 am
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - Mar 3rd, 2025 5:00 am
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth - Feb 11th, 2025 4:45 am